Mirum Pharmaceuticals, Inc.'s (NASDAQ: MIRM) lead product, Livmarli (maralixibat), an orally administered ileal bile acid transporter ("IBAT") inhibitor, is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) worldwide. Sales of Livmarli have been rising steadily since its approval and launch in 2021.
The FDA approved a label expansion for Livmarli oral solution to include the treatment of cholestatic pruritus in patients aged five years and older with progressive familial intrahepatic cholestasis ("PFIC") in March.
Also, during the second quarter of 2024, Livmarli was approved for treating cholestatic pruritus in PFIC patients aged 12 months and above in the United States.
The European Commission approved Livmarli for the treatment of PFIC in patients aged three months and older in July.
In the first half of 2024, Livmarli generated sales worth $90.1 million, up 46.3% on a year-over-year basis. The label expansion and the continuous demand for the drug should drive sales further in the days ahead.
Shares of Mirum have rallied 37.8% year to date against the industry's decrease of 1.7%.
Image Source: Zacks Investment Research
In ...
